Frontiers in Pharmacology (June 18): Review of Cell-Penetrating Peptides and Peptide Nucleic Acids for Targeted Diabetes Drug Delivery
Frontiers in Pharmacology published June 18 a review on enhancing diabetes treatment through targeted nucleic acid and drug delivery using cell-penetrating peptides (CPPs), peptide nucleic acids (PNAs), and receptor targeting. The paper maps how CPPs can shuttle therapeutic cargo across cellular membranes in pancreatic-beta-cell and insulin-resistance contexts and how PNAs can modulate gene expression in diabetic targets, addressing the persistent delivery problem that limits peptide and oligonucleotide therapy. The review framing intersects with the broader push toward oral peptide delivery (Entera Bio EB613, Foundayo) and platform-driven peptide-conjugate therapeutics (Bicycle, Parabilis Medicines, MultiValent Biotherapeutics) reshaping the obesity, diabetes, and oncology spaces in 2026.